The issue with mass-marketed compounded drugs like Wegovy extends beyond IP infringement. It attacks the fundamental "social contract" of biopharma: companies invest billions in R&D for a period of market exclusivity. Allowing compounded copies to bypass this system erodes the incentive for all future drug development.

While large pharmaceutical companies spend record amounts lobbying against drug pricing policies, the trade group for smaller biotechs has cut its spending to a 20-year low. This divergence highlights how immediate commercial threats, rather than broader FDA policy changes, are currently driving lobbying priorities for different segments of the industry.

Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

The Myriad Genetics case made naturally occurring compounds unpatentable. This removed the financial incentive for pharmaceutical companies to spend hundreds of millions on FDA trials for peptides, which are naturally derived. Compounding pharmacies filled the void until a 2023 FDA ban pushed these promising compounds into a risky, unregulated gray market.

Martin Shkreli claims that from a pharmaceutical development perspective, peptides are often avoided. They possess inherent weaknesses, being more complex than small molecules but less effective than large molecules like antibodies. This makes their recent popularity in biohacking circles ironic to industry insiders.

Major pharmaceutical companies are now willing to deploy the "nuclear option" of pulling planned R&D investments to express displeasure with national drug pricing policies. This tactic, seen in the UK, represents a direct and aggressive strategy to pressure governments into accepting higher prices for innovative medicines.

Andrew Huberman suggests that an impending crackdown on gray market peptides is motivated by pharmaceutical giant Eli Lilly's desire to protect its patent on Retatrutide, a potential trillion-dollar weight-loss drug. The push for regulation may be less about public safety and more about eliminating low-cost, gray-market alternatives to a blockbuster product.

The debate over Thymosin alpha-1 highlights a key market failure. Because it's an existing molecule that is difficult to patent, major pharmaceutical companies lack the financial incentive to fund expensive US FDA trials. This creates a vacuum where a potentially effective drug is only accessible through unregulated channels.

Martin Shkreli argues the pharmaceutical industry avoids peptides due to inherent weaknesses like short half-lives, viewing them as the 'worst of both worlds' compared to small molecules or antibodies. This perspective reframes the peptide craze as an elevation of a scientifically challenging and often impractical drug class.